Author Archives for Guest

Beyond Strategy: How Boards Can Accelerate ROI of a Deal

Published by

An old comic strip in my office shows the character Ziggy in a car facing two billboards: “Highway of Life” and “ Expect Delays.”  This sentiment seems to apply to Sanofi-Aventis’s prolonged merger negotiations with Genzyme. According to published reports, the apparent source of the delay has been agreement upon price, given the manufacturing problems at Genzyme. However, a bigger question the board must assess is whether senior management can address these issues within a timeframe that provides the expected return on investment. This situation is not unique. As opportunities for “bargain” deals resulting from performance problems become more plentiful... Read More